This week's View takes a look at which patients without known cardiovascular disease are most likely to experience net benefit from aspirin therapy for primary prevention, the outcomes with angioplasty with paclitaxel-coated balloon versus repeat stenting with drug-eluting stent in patients undergoing treatment for in-stent restenosis, and key points to remember from a JACC Review Topic of the Week on the cardiovascular toxicities of immune checkpoint inhibitors.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Angioplasty, Balloon, Angioplasty, Balloon, Coronary, Antilymphocyte Serum, Aspirin, Atrial Fibrillation, Bradycardia, Breast Neoplasms, Carcinoma, Renal Cell, Cardiac Imaging Techniques, Cardiomyopathies, Cardiotoxicity, Cardiovascular Diseases, Colorectal Neoplasms, Coronary Artery Disease, Coronary Restenosis, CTLA-4 Antigen, Drug-Eluting Stents, Electrocardiography, Hemorrhage, Hodgkin Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immune Tolerance, Immunoglobulins, Intravenous, Inflammation, Lymphoma, Magnetic Resonance Imaging, Melanoma, Myocardial Infarction, Myocardial Ischemia, Myocardial Revascularization, Myocarditis, Neoplasms, Paclitaxel, Pericarditis, Primary Health Care, Primary Prevention, Risk, Secondary Prevention, Stents, Risk Factors, Tachycardia, Tacrolimus, Thrombosis, Tobacco Use, Vasculitis, T-Lymphocytes, Arrhythmias, Cardiac, Dyslipidemias, Heart Failure

< Back to Listings